 |
TABLES OF RULES 2002
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS
| |
Mutations associated to resistance |
Mutations associated to « possible resistance » |
ZDV
|
T215Y/F
 |
At least 3 mutations among : M41L, D67N, K70R, L210W, T215D/C/S, K219Q/E
|
Q151M
Insertion at codon 69
|
T215D/C/S |
3TC
|
M184V/I
Insertion at codon 69
|
Q151M |
ddI
|
L74V
At least 3 TAMs including T215Y/F
Q151M
Insertion at codon 69
|
K65R |
ddC
|
No enough data to provide any recommendation |
No enough data to provide any recommendation |
d4T
|
V75M/S/A/T
T215Y/F
 |
At least 3 mutations among : M41L, D67N, K70R, L210W, T215D/C/S, K219Q/E
|
Q151M
Insertion at codon 69
|
T215D/C/S |
ABC
|
 |
At least 5 mutations among : M41L, D67N, L74V, M184V/I, L210W, T215Y/F
|
K65R and L74V and Y115F and M184V/I
Q151M
Insertion at codon 69
|
 |
4 mutations among : M41L, D67N, L74V, M184V/I, L210W, T215Y/F
|
K65R
|
TDF
|
Insertion at codon 69
3 TAMs including M41L or L210W
K65R
|
|
TAMs = M41L, D67N, K70R, L210W, T215Y/F, K219Q/E
ZDV: zidovudine, 3TC: lamivudine, ddI: didanosine, ddC: zalcitabine, d4T: stavudine, ABC: abacavir, TDF: tenofovir
|
 |